The vision of Handl Therapeutics is to deploy the power of disease modifying in vivo gene therapy to treat complex neurodegenerative diseases to start addressing significant unmet medical needs in healthcare.

Our business model is based on a highly integrative approach that is built on tight links with an international network of academic partners and close relationship with our partners.

Handl Therapeutics’ goal is to build a streamlined business that is designed to deliver transformative advanced medicines to the market.